Board of Directors at Codexis

As President & CEO of Codexis since August 2022, Stephen brings more than three decades of executive management experience in the biopharmaceutical industry. Most recently, he served as President and CEO of Sierra Oncology (NASDAQ: SRRA) through its recent sale to GlaxoSmithKline for $1.9 billion. Previously, Dr. Dilly served as CEO of Aimmune Therapeutics, acquired by Nestle Health Science for $2.6 billion. Dr. Dilly has served in executive roles at Genentech, Chiron and SmithKline Beecham and has been associated with the development, approval and launch of more than twenty marketed drugs across multiple therapeutic areas. He holds both an MBBS and a PhD in Cardiac Physiology from the University of London.

David V. Smith is the Chief Financial Officer and the Executive Vice President of Five Prime Therapeutics, Inc. Previously, he was the Chief Operating Officer of IntegenX, a privately held company focused on rapid DNA identification technology. In his past career he was the Executive Vice president and CFO of Thoratec Corporation, Vice President and CFO at Chiron Corp., Vice President and CFO of Anergen, Inc., and held various financial management positions with Genentech, Inc., IBM Corporation and Snytex Corporation. Mr. Smith previously served as a member of the board of directors of OncoGenex Pharmaceuticals Inc., a public biotechnology company. He received an MBA, Finance from Golden Gate University and a BA in Economics and History at Willamette University.

Byron Dorgan brings experience in policy making, government affairs and financial management having represented North Dakota in the U.S. Senate from 1992 to 2011 and in the House of Representatives from 1981 to 1992. He served as assistant Democratic floor leader, chairman of the Democratic Policy Committee and chairman of the Committee on Indian Affairs and also was the senior senator on the Appropriations, Energy and Commerce committees.

Prior to being elected to Congress, Mr. Dorgan served as North Dakota’s state tax commissioner from 1969 until 1980. The author of four books on governmental policy, Mr. Dorgan earned a bachelor’s degree from the University of North Dakota and an MBA from the University of Denver.

Esther Martinborough has over two decades of drug discovery, research and development expertise in the life sciences industry. She is Chief Scientific Officer at Escient Pharmaceuticals, a private biotechnology company, where she leads a team responsible for the company’s discovery and early development pipeline. Dr. Martinborough previously served for ten years as Executive Director, Head of Research and Senior Director, Head of Chemistry at Receptos-Celgene and Receptos, respectively, where she was responsible for transforming a pre-clinical academic asset into a potential best-in-class blockbuster drug, Zeposia® (ozanimod), for multiple xclerosis, which was the cornerstone of a multi-billion dollar acquisition by Celgene. Previously, Dr. Martinborough held positions at Vertex Pharmaceuticals, developing novel approaches to treating neuropathic pain, and at Ligand Pharmaceuticals, focusing on hormonal disfunctions. She earned her MA from the University of California, Los Angeles, received her PhD from the Swiss Institute of Technology, Zurich, and was a post-doctoral Fellow at the University of Illinois, Urbana-Champaign.

Stewart Parker has over 30 years of experience in the biotechnology industry. Since January 2009, Ms. Parker has served as a Principal at Parker BioConsulting, a biotechnology consulting firm. From March 2011 to June 2014, Ms. Parker served in various roles at the Infectious Disease Research Institute, a not-for-profit global health research institute, including as its Chief Executive Officer, strategic advisor and a member of the Board of Directors. Prior to that, Ms. Parker served in various roles of leadership at biopharmaceutical companies since 1992, including as Chief Executive Officer of Targeted Genetics Corporation, a publicly-traded biopharmaceutical company, which she founded. Since 2014, Ms. Parker has served on the Board of Directors of IMPEL Pharmaceuticals Inc., a publicly-traded pharmaceutical company, and Sangamo Therapeutics, Inc., a publicly-traded genomic therapies company. Ms. Parker also currently serves on the Board of Directors of various private companies. Previously, Ms. Parker served on the Board of Directors of Achieve Life Sciences, Inc., a publicly traded pharmaceutical company, from August 2017 to May 2021, and Armata Pharmaceuticals, Inc. (formerly C3J Therapeutics, Inc.), a publicly-traded biotechnology company, from May 2019 to December 2020. Ms. Parker also serves on the advisory boards of the University of Washington Foster School of Business and College of Arts & Sciences. Ms. Parker obtained a BA in Slavic Language & Literature and an MBA in Finance and International Business from the University of Washington.

Rahul Singhvi is a global leader in the Life Sciences industry and is cofounder and CEO of the biomanufacturing company, Resilience. Prior to cofounding Resilience in 2020, Rahul was an Operating Partner at Flagship Pioneering, where he was responsible for founding and operating companies launched from Flagship’s innovation foundry, Flagship labs. Before joining Flagship, Rahul was the Chief Operating Officer of Takeda’s Vaccine Business Unit where he was responsible for worldwide vaccine CMC and manufacturing operations. Before Takeda, Rahul was President and CEO of Novavax, Inc. where he transformed the company from a specialty pharmaceutical business into a leading vaccine company. Rahul’s career began at Merck & Co in 1994, where he held several positions of increasing responsibility in R&D and manufacturing. Rahul graduated as the top ranked chemical engineer from Indian Institute of Technology (IIT), Kanpur in India and earned both his masters and doctoral degrees in Chemical Engineering from MIT. He earned his MBA from the Wharton School at the University of Pennsylvania where he graduated as a Palmer Scholar. Rahul serves on the Board of Trustees of the Keck Graduate Institute, and on the Board of Directors for Codexis and Garuda Therapeutics.

Raymond De Vré brings over 20 years of executive-level experience to Codexis. He currently serves as the Chief Executive Officer and Managing Director at RADV Advisory, an independent strategic and operational advisory company focused on investments in the global healthcare and contract development and manufacturing organization (CDMO) space. He joined RADV from PolyPeptide Group, a CDMO focused on peptide- and oligonucleotide-based therapies for pharmaceutical and biotech companies globally, where he served as Chief Executive Officer. Prior to PolyPeptide, Dr. De Vré held multiple senior leadership roles at Dr. Reddy’s Laboratories, including Senior Vice President, Global Business Operations and Strategy, Biologics and Vice President, Commercial Biologics. Earlier in his career, he held roles of increasing responsibility at McKinsey & Company, ultimately ascending to the role of Partner. Dr. De Vré holds a PhD in Applied Physics from Stanford University and a master’s degree in engineering from Université Libre de Bruxelles.

As a retired CFO of DataStax, Inc. and previously as executive vice president and CFO of Fusion-io Multisystems and MySQL AB, Dennis Wolf brings significant experience in financial management, corporate finance and public company corporate governance to Codexis. Mr. Wolf also held financial management positions for public high-technology companies including Apple Computer, Centigram Communications, Credence Systems Corporation, Omnicell, Redback Networks and Sun Microsystems. He has been a director and chair of the audit committee for other public companies including Quantum Corporation, Avanex Corporation, Bigband Networks, Komag, Inc., Registry Magic, Vitria Technology and Exponential Interactive. Mr. Wolf earned a bachelor’s degree from the University of Colorado and an MBA from the University of Denver.